title: Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome.
abstract: OBJECTIVE
  The polymorphisms of the Fc receptor-like 3 gene (FCRL3), a novel immunoregulatory gene, have been shown to be associated with certain autoimmune diseases. This study was designed to examine whether the polymorphisms of FCRL3 are associated with susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Chinese population.
  
  
  METHODS
  A case-control study was performed in 230 Chinese VKH patients and 301 healthy controls. Four single nucleotide polymorphisms (SNPs; -169C/T, -110A/G, +358C/G, and +1381A/G) in FCRL3 were detected using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). human leukocyte antigen -DR4 (HLA-DR4) and HLA-DRw53 genotyping was performed using PCR techniques.
  
  
  RESULTS
  The results showed that the frequency of haplotype CACG was significantly lower in patients when compared with that in controls (p=0.0018, corrected p [pc]=0.0288). A significantly higher frequency was found for haplotype CGGG in HLA-DR4 negative patients than in HLA-DR4 negative controls (p=9.94 x 10(-8), Pc=1.59 x 10(-6)). There were no significant differences in the allele and genotype frequencies of the four investigated SNPs between VKH patients and controls. HLA-DR4 and HLA-DRw53 were significantly associated with VKH syndrome (p=3.21 x 10(-16) and p=7.08 x 10(-5), respectively). Stratification analysis according to HLA-DR4 and HLA-DRw53 did not show any association of FCRL3 polymorphisms with VKH syndrome.
  
  
  CONCLUSIONS
  Our study confirms the previous association of HLA-DR4 and HLA-DRw53 with VKH syndrome but fails to demonstrate an association between FCRL3 polymorphisms and VKH syndrome. Haplotype CACG might be a protective haplotype for VKH syndrome, and haplotype CGGG may be a risk haplotype in HLA-DR4 negative individuals.
authors.affiliation: The First Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
authors.forename: Ke
authors.initials: K
authors.lastname: Li
authors.forename: Peizeng
authors.initials: P
authors.lastname: Yang
authors.forename: Min
authors.initials: M
authors.lastname: Zhao
authors.forename: Shengping
authors.initials: S
authors.lastname: Hou
authors.forename: Liping
authors.initials: L
authors.lastname: Du
authors.forename: Hongyan
authors.initials: H
authors.lastname: Zhou
authors.forename: Aize
authors.initials: A
authors.lastname: Kijlstra
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D002681:China; D005260:Female; D006684:HLA-DR Antigens / Q000235:genetics; D015804:HLA-DR4 Antigen / Q000235:genetics; D059845:HLA-DRB4 Chains; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D011971:Receptors, Immunologic / Q000235:genetics*; D014607:Uveomeningoencephalitic Syndrome / Q000235:genetics*
chemical_list: C457775:FCRL3 protein, human; D006684:HLA-DR Antigens; D015804:HLA-DR4 Antigen; C050610:HLA-DR53; D059845:HLA-DRB4 Chains; D011971:Receptors, Immunologic